Abstract
Glutathione S-transferase (GST) was suggested as an important contributor to Alzheimer’s disease (AD). The GSTs polymorphisms have been investigated as candidate genetic risk factors for AD, yet results remained uncertain. Therefore, we performed a meta-analysis to clarify the relationship of GSTs polymorphisms with the occurrence of AD. PubMed, Embase, Cochrane library and Alzgene databases were searched and potential literatures were selected. Pooled analyses and subgroup analyses were conducted, and also publication bias tests and cumulative meta-analysis. This meta-analysis suggested null associations between polymorphisms of GSTM1, GSTT1, GSTM3, GSTP1, GSTO1 and AD risk. GSTs variants may not have an impact on the morbidity of Alzheimer’s disease. Further well designed researches are required to confirm these findings of the current study.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Alzheimer’s disease (AD) is becoming a heavy burden to the human society nowadays [1]. AD is a multifactorial disorder, involving genetic and environmental factors [1, 2]. One major contributor is the oxidative stress, which plays an important role in Alzheimer’s diseases (see reviews: [3, 4]). However, the antioxidants, e.g., glutathione (GSH), could be potentially therapeutic [5]. As a group of the key antioxidant enzymes, the Glutathione S-transferases (GSTs) regulate the maintenance of GSH and cellular detoxification, and are involved in the activation of signals in cell apoptosis [6]. GST contains several subtypes, i.e., GST alpha (A, α), mu (M, μ), Pi (P, π), omega (O, ω), theta (T, θ), etc. [6]. The levels of GST and enzymatic activity are reduced in brain and ventricular fluid in AD [7, 8]. Genetic variations in these enzymes could impact the risk of diseases [9].
There were several studies to reveal associations between polymorphisms of GSTs’ genes and AD. However, these findings were debated by other reports with inconsistent results. It was suggested that no pooled analysis concerning GSTs gene variants and risk of AD was documented. Therefore, we conducted the current meta-analysis to assess the effect of GSTs gene polymorphisms upon AD risk.
Materials and methods
Search strategy
To identify the relevant published articles based on the relationship of GSTs genetic polymorphisms and the risk of AD, we conducted a systematic literature search in PubMed, Embase, Cochrane library, and Alzgene databases up to March 2014. The following terms “genetic polymorphism or variants,” “Glutathione S-transferase or GST,” “Alzheimer’s disease or AD or Alzheimer” were used and language was not restricted. A manual search of references in the retrieved articles was also performed to find additional potential studies.
Inclusion criteria and exclusion criteria
Inclusion criteria should be met: (1) studies evaluated GSTs gene polymorphisms and AD; (2) case–control or cohort studies design; (3) genotype distributions could be obtained from articles, authors, or other sources (i.e., Alzgene database); (4) the largest sample size or the latest studies were selected in case of overlapped publications. Accordingly, exclusion would be made under any of the conditions: nonclinical studies; abstracts, reviews or opinions, conference reports, and case reports; articles with insufficient genotypic data that could not be calculated or obtained from other resource.
Data extraction
After reviewing the relevant articles thoroughly, the following data for each single nucleotide polymorphism (SNP) on GSTs were extracted from studies that met the inclusion criteria: first author, year of publication, country of participants, ethnicity of the population, and allele distributions in cases and controls.
Statistical analysis
We performed the combined analysis for the SNPs that had more than three studies involved. The association between GSTs genetic variants and risk of AD was measured by the odds ratio (OR) with 95 % confidence intervals (CI) according to our previous method [10]. The Cochran’s Q test and I 2 test were used to estimate heterogeneity across studies. If a significant heterogeneity (assigned as p value <0.1 and I 2 > 50 %) existed, the random effect Mantel–Haenszel model was chosen. To determine the statistical significance of the pooled OR, Z test was used with p < 0.05 as statistically significant. Pooled analysis was performed under different genetic models [10] (i.e., codominant model, dominant model, recessive model, additive model, and allele model) when necessary. Begg’s test and Egger’s test were applied to evaluate the evidence of publication bias; p value <0.05 in both tests was considered statistically significant. Further, subjects were stratified by ethnicity to perform subgroup analyses. And cumulative meta-analysis was conducted to evaluate the trend of pooled results from studies that subsequently accumulated until the recent year of publications [11]. Statistical analyses were performed using STATA software (SE 11.0 version, Stata Corporation, College Station, TX, USA).
Results
Screening and characteristics of related studies
The initial search yielded 281 potential papers (239 from PubMed, 10 from Embase, 0 from Cochrane library, and 32 from Alzgene database). There were 200 repeated literatures, 51 records of animal studies, and nonclinical research or not related with GSTs gene or Alzheimer’s disease among these articles. 13 documents were excluded because of insufficient genotypic data among cases and controls. According to the inclusion criteria, 17 articles [12–28], were finally selected for further analysis (see Fig. 1, literature selections in each stage). Among these articles, genetic polymorphisms of GSTM1, GSTM3, GSTT1, GSTP1, and GSTO1 were studied in more than three researches. Most of the related studies only provided the distributions of present (+/+ and +/−) and null (−/−) alleles in GSTM1 and GSTT1 genes. The basic characteristics of all the included studies are shown in Table 1.
Results of heterogeneity tests
Evidence of heterogeneity was observed among studies within the included GSTs SNPs(see Table 2, heterogeneity results of I 2 and p value). Therefore, random effects pooling model was used to calculate the combined ORs for all SNPs in AD.
GSTM1 (present versus null) alleles
In summary, results of meta-analysis failed to show any influence of GSTM1 on the risk of AD among either overall population (OR = 0.988, 95 % CI 0.647–1.509; z = 0.06, p = 0.955), or Caucasians, Asians, or other populations (see Fig. 2; Table 2).
GSTT1 (present versus null) alleles
A null association of GSTT1 in AD samples was found by the meta-analysis among overall population or Caucasians. A potential relationship was revealed in Asians for AD (OR = 0.405, 95 % CI 0.182–0.900; z = 2.22, p = 0.027); however, with only one study involved, this needs to be confirmed in the future (see Fig. 2; Table 2).
GSTM3 rs7483 (G/A)
Summary ORs and 95 % CIs were evaluated under different inherited models to estimate the correlation of GSTM3 rs7483 with AD risk. The results did not show any significant effect of GSTM3 rs7483 within each genetic model. Further subgroup analyses also found significant impact of GSTM3 rs7483 on AD risk in other population (one study was involved), but not in overall and Caucasian populations (see Table 2).
GSTP1 rs1695 (Ile105Val, A/G)
A meta-analysis was carried out for GSTP1 rs1695 in AD under different genetic models, and we did not find associations between GSTP1 rs1695 and AD risks among overall and Caucasian populations (see Table 2).
GSTO1 rs4925 (C/A), rs1804834 (A/G)
According to the pooling analysis and subgroup analysis, lack of significant effect of GSTO1 rs4925 on AD morbidity was concluded. The combined ORs and 95 % CI values under related inherited models are shown in Table 2.
Publication bias and cumulative analysis
Begg’s and Egger’s tests indicated no evidence of significant asymmetry for most of the related GSTs SNPs within Alzheimer’s disease (see Table 3).
In the cumulative meta-analyses, the evidences were observed to support the pooling analyses regarding relevant GSTs SNPs and AD (see Fig S1).
Discussion
Effects of GSTs genetic polymorphisms and ethnicity in neurodegenerative diseases [29] are of our interest. Combined analyses concerning GSTs SNPs in Alzheimer’s disease have not been reported yet. To the best of our knowledge, this is the first meta-analysis discussing GSTs polymorphisms among AD subjects. In this study, a total of 17 articles regarding SNPs of GSTM1, GSTT1, GSTM3, GSTP1, and GSTO1 genes were evaluated in AD. No significant effect of GSTM1 or GSTT1 present polymorphism was observed in Alzheimer’s disease in the pooled analyses. We used several genetic models to assess the roles of GSTM3, GSTP1, and GSTO1 genetic variants in AD; however, we found null associations between these GSTs SNPs and AD risk.
rs1332018 (C/A), rs1799735 (del/AGG) of GSTM3 [21]; GSTP1 Ala114Val (GSTP1*A/*B/*C/*D) [15, 24, 30]; GSTP1 C341T [24] and GSTO1 rs1804834 [27, 31] were also reported in AD. We did not perform any pooled analysis on these SNPs in AD because the relevant studies were limited.
Some potential limitations should be taken into consideration. First, the relative small global sample size and the number of cases in some ethnic subgroups were shortcomings, considering small or inadequate samples could lead to misleading results. Moreover, other GSTs genes, e.g., GSTA1, GSTO2, may also play a role in the development of Alzheimer’s disease. One research [18] suggested that GSTA1 rs3957356 was associated with the increased AD in Dominant model. Positive effect of rs156697 on GSTO2 was also found [32] among older (>80 years old) AD patients. Third, there was an evidence of heterogeneity in the current meta-analysis. One potential explanation to the heterogeneity is the influence of ethnic background or environment [2] in the correlation of gene variants with AD. Heterogeneity could also come from individual clinical study.
In conclusion, our meta-analysis suggested that SNPs of the relevant GSTs (GSTM1, GSTT1, GSTM3, GSTP1, and GSTO1) did not confer risk for AD. Further well-designed researches are needed to confirm these findings, especially in the subsets with limited studies involved in the current study.
References
Reitz C, Mayeux R (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem Pharmacol 88:640–651
Armstrong RA (2013) What causes Alzheimer’s disease? Folia Neuropathol 51:169–188
Ellis EM (2007) Reactive carbonyls and oxidative stress: potential for therapeutic intervention. Pharmacol Ther 115:13–24
Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer’s disease. Oxid Med Cell Longev 2013:316523
Pocernich CB, Butterfield DA (2012) Elevation of glutathione as a therapeutic strategy in Alzheimer disease. Biochim Biophys Acta 1822:625–630
Raza H (2011) Dual localization of glutathione S‐transferase in the cytosol and mitochondria: implications in oxidative stress, toxicity and disease. FEBS J
Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology 51:1562–1566
Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69:155–167
Da Costa LA, Badawi A, El-Sohemy A (2012) Nutrigenetics and modulation of oxidative stress. Ann Nutr Metab 60(Suppl 3):27–36
Wang T (2014) Meta-analysis of PvuII, XbaI variants in ESR1 gene and the risk of Alzheimer’s disease: the regional European difference. Neurosci Lett 574C:41–46
Mullen B, Muellerleile P, Bryant B (2001) Cumulative meta-analysis: a consideration of indicators of sufficiency and stability. Pers Soc Psychol, Rev
Green VJ, Pirmohamed M, Kitteringham NR et al (1995) Glutathione S-transferase mu genotype (GSTM1*0) in Alzheimer’s patients with tacrine transaminitis. Br J Clin Pharmacol 39:411–415
Stroombergen MC, Waring RH (1999) Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease. Hum Exp Toxicol 18:141–145
Nicholl DJ, Bennett P, Hiller L et al (1999) A study of five candidate genes in Parkinson’s disease and related neurodegenerative disorders. Neurology 53:1415–1421
Bernardini S, Bellincampi L, Ballerini S et al (2005) Glutathione S-transferase P1 *C allelic variant increases susceptibility for late-onset Alzheimer disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem 51:944–951
Pinhel MAS, Nakazone MA, Cação JC et al (2008) Glutathione S-transferase variants increase susceptibility for late-onset Alzheimer’s disease: association study and relationship with apolipoprotein E epsilon4 allele. Clin Chem Lab Med 46:439–445
Ghosh T, Mustafa M, Kumar V et al (2012) A preliminary study on the influence of glutathione S transferase T1 (GSTT1) as a risk factor for late onset Alzheimer’s disease in North Indian population. Asian J Psychiatr 5:160–163
Piacentini S, Polimanti R, Squitti R et al (2012) GSTM1 null genotype as risk factor for late-onset Alzheimer’s disease in Italian patients. J Neurol Sci 317:137–140
Piacentini S, Polimanti R, Squitti R et al (2012) GSTO1*E155del polymorphism associated with increased risk for late-onset Alzheimer’s disease: association hypothesis for an uncommon genetic variant. Neurosci Lett 506:203–207
De Sousa M, Pirmohamed M, Kitteringham NR et al (1998) No association between tacrine transaminitis and the glutathione transferase theta genotype in patients with Alzheimer’s disease. Pharmacogenetics 8:353–355
Hong G-S, Heun R, Jessen F et al (2009) Gene variations in GSTM3 are a risk factor for Alzheimer’s disease. Neurobiol Aging 30:691–696
Maes OC, Schipper HM, Chong G et al (2010) A GSTM3 polymorphism associated with an etiopathogenetic mechanism in Alzheimer disease. Neurobiol Aging 31:34–45
Bullock JM, Medway C, Cortina-Borja M et al (2013) Discovery by the Epistasis Project of an epistatic interaction between the GSTM3 gene and the HHEX/IDE/KIF11 locus in the risk of Alzheimer’s disease. Neurobiol Aging 34(1309):e1–e7
Žuntar I, Kalanj-Bognar S, Topic E et al (2004) The glutathione S-transferase polymorphisms in a control population and in Alzheimer’s disease patients. Clin Chem Lab Med. doi:10.1515/cclm.2004.059
Giedraitis V, Kilander L, Degerman-Gunnarsson M et al (2009) Genetic analysis of Alzheimer’s disease in the Uppsala Longitudinal Study of Adult Men. Dement Geriatr Cogn Disord 27:59–68
Kölsch H, Linnebank M, Lütjohann D et al (2004) Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Neurology 63:2255–2260
Ozturk A, Desai PP, Minster RL et al (2005) Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer’s disease. Neurobiol Aging 26:1161–1165
Capurso C, Panza F, Seripa D et al (2010) Polymorphisms in glutathione S-transferase omega-1 gene and increased risk of sporadic Alzheimer disease. Rejuvenation Res 13:645–652
Wang T, Wang B (2014) Association between Glutathione S-transferase M1/Glutathione S-transferase T1 polymorphisms and Parkinson’s disease: a meta-analysis. J Neurol Sci 338:65–70
Singh NK, Banerjee BD, Bala K et al (2014) Polymorphism in cytochrome P450 2D6, glutathione S-transferases Pi 1 genes, and organochlorine pesticides in Alzheimer disease: a case-control study in North Indian population. J Geriatr Psychiatry Neurol 27:119–127
Andrukhova O, Salama M, Rosenhek R et al (2012) Serum glutathione S-transferase P1 1 in prediction of cardiac function. J Card Fail 18:253–261
Allen M, Zou F, Chai HS et al (2012) Glutathione S-transferase omega genes in Alzheimer and Parkinson disease risk, age-at-diagnosis and brain gene expression: an association study with mechanistic implications. Mol Neurodegener 7:13
Acknowledgments
The author thanks Xiang Li for his excellent work in article screening and data extraction.
Conflict of interest
None declared.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Wang, T. Glutathione S-transferases variants as risk factors in Alzheimer’s disease. Neurol Sci 36, 1785–1792 (2015). https://doi.org/10.1007/s10072-015-2245-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-015-2245-7